Oxelumab

Drug Profile

Oxelumab

Alternative Names: Anti-OX40L - Genentech; huMAb OX40L; OX40L huMab; R4930; RG 4930; RO4989991; Roche 4

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Genmab; Roche
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic asthma; Allergic rhinitis

Most Recent Events

  • 30 Jun 2011 Discontinued - Phase-I for Allergic rhinitis in USA (IV)
  • 30 Jun 2011 Discontinued - Phase-II for Allergic asthma in Canada (IV)
  • 30 Apr 2011 Roche completes a phase I trial in Allergic rhinitis in USA (NCT01152619)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top